Japan drug firms seek new growth outlets: companies shift plans in bid to tap product pipelines
Article Abstract:
Because of impending drug patent expirations and subsequent revenue losses, Japanese pharmaceutical companies seek to grow through reorganization, corporate acquisitions, and investments on new product development. Article discusses Japanese drug companies's sales, cost control, strategic planning, and international competitiveness.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
Sales of key drugs lift net at Astellas, Eisai
Article Abstract:
Fiscal third-quarter net profits for Japanese pharmaceutical firms Eisai Company Ltd. and Astellas Pharma Inc. rose on strong sales. Net profit for Eisai rose 3.5% to 24.16 bil yen, with an increase in sales of 8.5%. Net profit for Astellas rose 52% to reach 161.24 bil yen, with sales increasing by 8.9%.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
Big drug makers in Japan report mixed results
Article Abstract:
First-quarter net profits for Japanese pharmaceutical companies showed both increases and losses. While Astellas Pharma Inc. had a 27% rise, Daiichi Sankyo Co. posted a 10% loss, and Eisai Company Ltd. reached a record net profit.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Germany's cartel office probes 35 gas companies. Gazprom drills deeper into Europe
- Abstracts: Faurecia sees slowdown after cutting year's loss: slump to brake sales of auto parts in '08; goal is to trim debt
- Abstracts: Pearson to sell German FT stake. BAE Systems sets integration deadline. Informa adds databases with Datamonitor deal: information provider continues expansion in $995 million pact